India has a chance to claim space in the global biotech sector being vacated by the United States, but only if it stops thinking of itself as the world's back office.
According to an opinion piece published on MSN (via Bing News), too much of Indian life sciences still operates as if the country's highest calling is to serve as a low-cost execution arm for others. In other words, India often takes on contract work — making and testing what companies elsewhere design — rather than leading the science itself.
The argument is that this is a moment of opportunity. As the US steps back from parts of the biotech field, a gap is opening that another country could move into. The piece frames India as well-positioned to capture that space, provided it shifts from a service mindset to one of originating its own research, products, and direction.
The source does not detail specific policies, companies, or figures behind this shift; it makes the broader case that ambition, not just capacity, is what India's life sciences sector now needs.
Why it matters: biotech shapes everything from new medicines to the cost of healthcare, so which countries lead it determines who sets the priorities — and reaps the rewards — of the next generation of scientific breakthroughs.